PTO/SB/08a (08-03)

Approved for use through 07/31/2006, OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

First Named Inventor
Art Unit

(Use as many sheets as necessary)

Examiner Name

Sheet

Attorney Docket Number

			U. S. PATENT D	OCUMENTS	
Examiner Initials*	Cite No.	Document Number  Number-Kind Code <sup>2 (# known)</sup>	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
/D.J./		us-6, 432, 991	08-13-2002	Thomas IN	pages 1-13
		US-6,635,667	10-21-2003	Thomas, TN	Pages 1-13
		US-6,482,846	11-19-2002	Garvey DS. et al	Pages 1-33
		US-6.593,347	07-15-2003	Bandazage UK. et al.	pages 1-15
		US-6.544.556	04-08-2003	Chen CM, et al	Pages 1-14
V		US-6.613.7X4	09-02-2003	Benedini F, et al	Pages 1-10
/D.J./		US-6.649.629	11-18-2003	Bandarage UK etal	pages 1-40
		US.	,		, 0
		US-			
		US-	·		
		US-			

FOREIGN PATENT DOCUMENTS						
Examiner Initiats*	Cite No.1	Foreign Patent Document  Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>8</sup> (# known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
************		> 1 c + 2 c		***************************************	***************************************	
*************			***************************************	***************************************		L
*******				• • • • • • • • • • • • • • • • • • •		L
***********		***************************************		 		Ļ

Examiner Date	
Signature Considered Considered	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patient Documents at <a href="https://www.uspio.gov">www.uspio.gov</a> or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patient documents, the indication of the year of the reign of the Emperor must precede the serial number of the patient document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the Individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 1449B/PTO	Complete If Known		
	Application Number		
INFORMATION DISCLOSURE	Filing Date	Thomas N. Thomas	
STATEMENT BY APPLICANT	First Named Inventor	THOMAS N. THOMAS	
4,	Art Unit		
(Use as many sheets as necessary)	Examiner Name		
Sheet of /	Attorney Docket Number		

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.  Lauer MS. Aspirin for primary prevention of coronary events. N Engl J Med, 346: 1468-1474, 2002.	
/D.J./	-1		
	2	Fennerty BM. NSAID-related gastrointestinal injury. Postgraduate Medicine, 110: 87-94, 2001.	<b>/</b>
	3	Yeomans ND. Approaches to healing and prophylaxis of nonsteroidal antiinflammatory Drug-associated ulcers. Am. J. Medicine. 110/1A: 24S - 28S, 2001	<b>/</b>
	4	GlavinGB, et al. L-deprenyl attennuates stress ulcer formation in rats. Neurosci. Letters. 70: 379-381 (1986).	<b>/</b>
	5	ThyagaRajan S. Anti-tumor effect of I-deprenylin rats with carcinogen-induced Mammary tumors. J. Neuroimmunol. 109: 95-104, 2000.	/
	6	Thomas, T; et al. L-Deprenyl: nitric oxide productionand dilation of cerebral blood vessels. NeuroReport, 9:1-6, 1998	<b>/</b>
	7	Thomas, T. Monoamine oxidase-B inhibitors in the treatment of Alzheimer's disease.  Neurobiol. Aging. 21:343-348, 2000.	1
	8	Thomas T,et al. Aspirin and diabetes: inhibition of amylin aggregation by nonsteroidal Antiinflammatory drugs. Exp Clin Endocrinol Diabetes. 111: 8-11, 2003.	/
$\sqrt{}$	9	Thomas, T. et al. Inhibition of LDL oxidation by the neuroprotective drug I-deprenyl.  Neurol. Res. 24:169-173, 2002	<b>/</b>
/D.J./	10	Wallace JL and Soldato DL. The therapeutic potential of NO-NSAIDS. Fundamental & Clin Pharmacol. 17: 11-20, 2003.	/

Examiner Signature	/Donna Jagoe/	Date Considered	12/28/2007

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

considered, include copy or this form with next communication to applicant.

1 Applicant's unique dilation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete. on the amount of time you require to complete this form and/or suggestions for reducing the burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.